To evaluate the effect of photodynamic therapy (PDT) as adjuvant treatment, after brachytherapy, in posterior amelanotic choroidal melanomas.
Methods
Six patients with posterior amelanotic choroidal melanoma underwent brachytherapy treatment. Tumour response was assessed by fundus examination, fundus photography and A-B scan ultrasonography. The residual tumours were treated with adjuvant PDT performed with infusion of verteporfin intravenously at 6 mg/m2 body surface area. Five minutes after infusion, a 689 nm laser was applied with a light dose of 100 J/cm2 over an interval of 166 s.
Results
At a median follow-up after brachytherapy of 17.5 months (IQR 16.2–22.5, range 5–42 months), tumours showed a partial reduction of tumour thickness (22.5% as compared to baseline value) and persistent low internal reflectivity at A-B scan ultrasonography. Supplementary photodynamic treatment resulted in complete resolution of the lesion with marked decrease of elevation . Mean decrease in thickness after PDT was 49.9% with respect to previous brachytherapy treatment 22.5% (p = 0.007). The results was achieved within a median period of 4 months (range 2–4 months) after PDT, and there has been no recurrence after a median follow-up of 84.7 months ± 18.7 (range 59 to 107 months).
Conclusion
Combined treatment of brachytherapy and adjuvant PDT in amelanotic uveal melanoma seems to be favourable with regard to complete and rapid tumour regression.
Collaborative Ocular melanoma Study Group. The COMS randomized trial of Iodine 125 brachytherapy for choroidal melanoma: twelve-year mortality rates and prognostic factors: COMS report N°28. Acta Ophthalmol2006 Dec; 12412: 1684–1693.
2.
KaisermanIAntebyIChowersI,et al.Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy. Ophthalmol2002; 109: 1137–1141.
3.
Pe’erJStefaniFHSeregardS, et al.Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study. Br J Ophthalmol2001; 85: 1208–1212.
4.
ShieldsCLCaterJShieldsJA, et al.Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol2002; 120: 933–940.
5.
ShieldsJAShieldsCL. Posterior uveal melanoma management. In: ShieldsJAShieldsCL (eds) Intraocular tumors: an atlas and textbook, 2nd ed. Philadelphia: Lippincott, Williams & Wilkins, 2008, pp.140–175.
6.
TagliaferriLPagliaraMMFiondaB, et al.Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review. J Contemp Brachytherapy2019; 11: 54–60.
7.
NaidooCKrugerCAAbrahamseH. Photodynamic therapy for metastatic melanoma treatment: a review”. Technol Cancer Res Treat2018 Jan 1; 17: 1–15.
8.
KataokaHNishieHHayashiN, et al.New photodynamic therapy with next-generation photosensitizers. Ann Transl Med2017; 5: 183.
9.
BarbazettoISchmid-ErfurthU. ”Photodynamic therapy of choroidal hemangioma : two case reports.”. Graefe’sArch Clin exp Ophthalmol2000; 238: 214–221.
10.
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin:one year results of 2 randomized clinical trials-tap report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol1999; 117: 1329–1345.
11.
DonaldsonMJLimLHarperCA,et al.Primary treatment of choroidal amelanotic melanoma with photodynamic therapy. Clin Experiment Ophthalmol2005; 33: 548–549.
12.
FavillaIFavillaMLGosbellAD,et al.Photodinamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res1995; 5: 355–364.
13.
QuhillHGoslinDSearsK,et al.Primary photodynamic therapy for small amelanotic choroidal melanomas: consecutive case series of 69 patients with at least 24-months follow-up. Br J Ophthalmol2020; 0: 1–6.
14.
SoucekPCihelkovaI. Photodynamic therapy with verteporfin in subfoveal amelanotic choroidal melanoma (A controlled case). Neuro Endocrinol Lett2006; 27: 145–148.
15.
CampbellWGPejnovicTM. Treatment of amelanotic choroidal melanoma with photodynamic therapy. Retina2012; 32: 1356–1362.
16.
RundleP. Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br J Ophthalmol2014; 98: 494–497.
17.
O’DayRFPejnovicTMIsaacsT, et al.Australian and New Zealand study of photodynamic therapy in choroidal amelanotic melanoma. Retina2020; 40: 972–976.
18.
WachtlinJBechrakisNEFoersterMH. Photodynamic therapy with verteporfin for uveal melanoma ”. Ophthalmologe2005; 102: 241–246.
19.
YordiSSotoHBowenRC,et al.Photodynamic therapy for choroidal melanoma: what is the response rate?Surv Ophthalmol2021Jul-Aug; 66: 552–559.
20.
MazloumiMDAlvinLAbtahiS-H, et al.Photodynamic theraphy in ocular oncology. J Ophthalmic Vis Res2020 Oct 25; 15: 547–558.
21.
BarbazettoIALeeTCRollinsIS,et al.Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol2003; 135: 898–899.
22.
TuncerSKirNShieldsCL. Dramatic regression of amelanotic choroidal melanoma with PDT following poor response to brachytherapy. Ophthalmic Surg Lasers Imaging2012; 43: e38–e40.
23.
LeeDSAndersonSFPerezEM,et al.Amelanotic choroidal nevus and melanoma: citology, tumor size, and pigmentation as prognostic indicators. Optom Vis Sci2001; 78: 483–491.
24.
MaheshwariAFingerPT. Regression patterns of choroial melanoma after palladium-103 brachytherapy. European J of Ophthalmol2018; 28: 722–730.
SharmaKVBowersNDavidsLM.Photodynamic therapy induced killing is enhanced in depigmented metastatic melanoma cells. Cell Biol Int2011; 35: 939–944.
28.
Novak-AndrejcicKBorisJHawlinaM. Echografic follow-up of malignant melanoma of the choroid after brachytherapy with 106Ru. Klin Monbl Augenheilkd2003 Dec; 220: 853–860.
29.
ChenBPogueBWHoopesPJ,et al.Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr2006; 16: 279–305.
30.
BrownMJWilsonWR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer2004; 4: 437–447.
31.
LiuJNBuWShiJ. Chemical design and sunthesis of functionalized probes for imaging and treating tumor hypoxia. Chem Rev2017; 117: 6160–6224.
32.
BroekgaardenMWeijerRvan GulikTM,et al.Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Re201534: 643–690.
33.
WilsonWRHayMP. Targeting hypoxia in cancer therapy. Nat Rev Cancer2011; 11: 393–410.
34.
SharmaAArambulaJFKooS, et al.Hypoxia-targeted drug delivery. Chem Soc Rev2019; 4: 771–813.
35.
GrahamKUngerE. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine2018; 13: 6049–6058.
36.
FreitasI. Facing hypoxia: a must for photodynamic therapy. J Photochem Photobiol B1988; 2: 281–282.
37.
PriceMHeilbrunLKesselD. Effects of the oxygenation level on formation of different reactive oxygen species during photodynamic therapy. Photochem Photobiol2013; 89: 683–686.
38.
LarueLMyrzakhmetovBBen-MihoubA, et al.Fighting hypoxia to improve PDT. Pharmaceuticals (Basel)2019; 12: 163.
39.
MazeronJJScallietPVan LimbergenE,et al.Radiobiology of brachytherapy and the dose-rate effect. Medicine Physics 2013.
40.
LiJXueYTianJ, et al.Fluorinated -functionalized hyaluronic acid nanoparticles for enhanced photodynamic therapy of ocular choroidal melanoma by ameliorating hypoxia. Carbohydr Polym2020 Jun 1; 237: 116–119.
